Oxford, UK – 9 November 2006: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that Dr. Robert Amato has presented further encouraging data from three Phase II trials of TroVax, the Company’s lead cancer immunotherapy product, in renal cell carcinoma and prostate cancer at the 18th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”, which is being held on 7-10 November 2006 in Prague, Czech Republic.
